Dhiren Patel
Addiction Psychiatry · Dallas, TXNPI 1528078466
Payments from drug & device makers
Across 1,058 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- Otsuka America Pharmaceutical, Inc.$3K
- AbbVie$1K
- Lundbeck LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $8K from 34 others
What the payments were for
- Speaking & faculty fees$2,25011%
- Travel & lodging$6143%
- Food & beverage$17,76586%
- Education$960%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$3,173
- REXULTI$577
- CAPLYTA$232
- VRAYLAR$125
- Dyanavel XR$115
- Quillichew ER$115
- Quillivant$115
- SUBLOCADE$108
How this compares
$20,725 in reported general payments places this provider in the 95th percentile of 25 addiction psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 163 | $12,974 |
| VyvanseLisdexamfetamine Dimesylate | 32 | $12,192 |
| Effexor XrVenlafaxine Hcl | 13 | $7,032 |
| Lisdexamfetamine Dimesylate | 36 | $6,768 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $5,660 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 131 | $4,845 |
| Doxepin Hcl | 36 | $2,288 |
| Buprenorphine Hcl | 57 | $1,867 |
| Methylphenidate Hcl | 22 | $1,186 |
| Bupropion XlBupropion Hcl | 64 | $1,081 |
| Clonazepam | 107 | $1,006 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 15 | $993 |
| Olanzapine | 15 | $613 |
| Trazodone Hcl | 69 | $546 |
| Duloxetine Hcl | 45 | $544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl | $21 | $14,841220 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $1,302 | $12,19232 claims |
| Indivior Inc.Suboxone | $833 | $5,66014 claims |
| Almatica Pharma LLCSertraline Hcl | $587 | $35013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 addiction psychiatry providers in Texas.
Other addiction psychiatry in Dallas
- Harold UrschelDallas$6K
- Bryon AdinoffDallas$131
- Sidarth WakhluDallas$85
- Robert WoodhamHouston$14K
- Ivanshu JainTerrell$2K
- Julie PittmanArlington$557
- Qingmin RuanHouston$510
- Neelofar LalaniCarrollton$471
- David TuckerDenton$327
- Reza SafaviHouston$307
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.